JNJ-89862175

**JNJ-89862175** is an investigational **antibody-drug conjugate (ADC)** developed by **Janssen Research & Development, LLC** (Johnson & Johnson) that targets **ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3)**, a protein highly expressed on various solid tumor cells including kidney, ovarian, uterine, lung, and colorectal cancers. It is designed to deliver cytotoxic payloads selectively to ENPP3-expressing tumors, minimizing off-target effects on normal tissues where ENPP3 expression is low. Currently in a **Phase 1 clinical trial (NCT07223125)** evaluating safety, tolerability, dose escalation, and preliminary efficacy in patients with advanced unresectable or metastatic **lung adenocarcinoma, renal cell carcinoma (clear cell or papillary), endometrioid ovarian cancer, and endometrioid uterine carcinoma**, with oral administration and ongoing dose expansion planned.[3][4][5][7][8]